U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H25N5O4
Molecular Weight 459.4971
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APIXABAN

SMILES

COC1=CC=C(C=C1)N2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O

InChI

InChIKey=QNZCBYKSOIHPEH-UHFFFAOYSA-N
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

HIDE SMILES / InChI
Molecular Formula C25H25N5O4
Molecular Weight 459.4971
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Apixaban is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. Apixaban has been available in Europe since May 2012. An FDA decision on apixaban which was expected on June 28, 2012 was initially delayed before final approval on December 28, 2012. On August 21, 2014, Pfizer announced that apixaban was now FDA approved for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Apixaban is substrate of p-glycoprotein (p-gp), a ubiquitous transmembrane receptor found in the intestinal wall, as well as various other locations in the body, including the blood-brain barrier. P-gp actively transports molecules with diverse conformations, including drugs, across tissue monolayers.

Originator

Bristol-Myers Squibb
144
Curator's Comment: In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field. # Bristol-Myers Squibb

Approval Year

2012
608
Targets

Targets

Primary TargetPharmacologyConditionPotency
Coagulation factor X
21
Target ID: P00742
Gene ID: 2159.0
Gene Symbol: F10
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.22 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8583
ELIQUIS

Approved Use

Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.

Launch Date

2012
Secondary
Approved
8583
ELIQUIS

Approved Use

Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery; for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
207 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23488672/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
APIXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2024 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23488672/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
APIXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23488672/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
APIXABAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
50 mg single, oral
Highest studied dose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30498375
healthy, 20-39 years
Health Status: healthy
Age Group: 20-39 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/30498375
Sources:
https://pubmed.ncbi.nlm.nih.gov/30498375
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/33278889
unknown, 23 months
Health Status: unknown
Age Group: 23 months
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/33278889
Other AEs: Intoxication...
Other AEs:
Intoxication
Sources:
https://pubmed.ncbi.nlm.nih.gov/33278889
2.5 mg 2 times / day steady, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 2.5 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 19-39 years)
Health Status: healthy
Age Group: 27 years (range: 19-39 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (1 patient)
Nausea (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
25 mg 2 times / day steady, oral
Highest studied dose
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 20-41 years)
Health Status: healthy
Age Group: 27 years (range: 20-41 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Other AEs: Haematochezia, Alanine aminotransferase increased...
Other AEs:
Haematochezia (1 patient)
Alanine aminotransferase increased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
210 mg single, oral
Overdose
Dose: 210 mg
Route: oral
Route: single
Dose: 210 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/28964584
unknown, 48 years
Health Status: unknown
Age Group: 48 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/28964584
Other AEs: Poisoning...
Other AEs:
Poisoning
Sources:
https://pubmed.ncbi.nlm.nih.gov/28964584
2.5 mg 1 times / day steady, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 2.5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30569731
unhealthy, 85 years
Health Status: unhealthy
Age Group: 85 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/30569731
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30569731
25 mg 2 times / day steady, oral
Overdose
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
5 mg 2 times / day steady, oral
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
Other AEs: Thromboembolic event...
Other AEs:
Thromboembolic event
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Intoxication
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/33278889
unknown, 23 months
Health Status: unknown
Age Group: 23 months
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/33278889
Headache 1 patient
Disc. AE
2.5 mg 2 times / day steady, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 2.5 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 19-39 years)
Health Status: healthy
Age Group: 27 years (range: 19-39 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Nausea 1 patient
Disc. AE
2.5 mg 2 times / day steady, oral
Dose: 2.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 2.5 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 19-39 years)
Health Status: healthy
Age Group: 27 years (range: 19-39 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Alanine aminotransferase increased 1 patient
25 mg 2 times / day steady, oral
Highest studied dose
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 20-41 years)
Health Status: healthy
Age Group: 27 years (range: 20-41 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Haematochezia 1 patient
25 mg 2 times / day steady, oral
Highest studied dose
Dose: 25 mg, 2 times / day
Route: oral
Route: steady
Dose: 25 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
healthy, 27 years (range: 20-41 years)
Health Status: healthy
Age Group: 27 years (range: 20-41 years)
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/23451769
Poisoning
210 mg single, oral
Overdose
Dose: 210 mg
Route: oral
Route: single
Dose: 210 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/28964584
unknown, 48 years
Health Status: unknown
Age Group: 48 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/28964584
Hepatotoxicity 1 patient
Disc. AE
2.5 mg 1 times / day steady, oral
Dose: 2.5 mg, 1 times / day
Route: oral
Route: steady
Dose: 2.5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30569731
unhealthy, 85 years
Health Status: unhealthy
Age Group: 85 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/30569731
Thromboembolic event
5 mg 2 times / day steady, oral
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
substrate
1193

inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2C8
1057

CYP3A4/5
296

CYP2C19
2057

P-gp
1741
P-gp
2052

CYP1A2
1197

CYP2C8
810

CYP2C19
1119

CYP2J2
71

MRP
9

OATP1B1
503

OATP1B3
435

OATP2B1
122

OAT1
395

OAT3
391

BCRP
697
CYP1A2
832

CYP2B6
669

CYP3A4/5
133
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
2141
 minor [IC50 20 uM]
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2A6
911
 no
CYP2B6
1160
 no
CYP2B6
1160
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP3A4/5
357
 no
CYP3A4/5
357
 no
P-gp
1932
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1197
 minor
CYP2C19
1119
 minor
CYP2C8
810
 minor
CYP2C9
1193
 minor
CYP2J2
71
 minor
MRP
9
 no
OAT1
395
 no
OAT3
391
 no
OATP1B1
503
 no
OATP1B3
435
 no
OATP2B1
122
 no
BCRP
697
 yes
CYP3A4
1946
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of apixaban 1.5x, auc 2x
Page: 9.0
P-gp
2052
 yes
yes (co-administration study)
Comment: ketoconazole increased cmax of apixaban 1.5x, auc 2x
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:72296
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:72296
ChemicalBook
CB51508586
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51508586
eMolecules
32278100
https://www.emolecules.com/cgi-bin/more?vid=32278100
MolPort
MolPort-006-170-153
https://www.molport.com/shop/molecule-link/MolPort-006-170-153
Selleck Chemicals
Apixaban(BMS-562247-01)
http://www.selleckchem.com/products/Apixaban(BMS-562247-01).html
ZINC
ZINC000011677837
http://zinc15.docking.org/substances/ZINC000011677837
PubMed

PubMed

TitleDatePubMed
New antithrombotics for atrial fibrillation.
2010-10
Novel oral anticoagulants: implications in the perioperative setting.
2010-09
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
2010-09
New antithrombotic agents--insights from clinical trials.
2010-09
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
2010-09
Treatment of thromboembolism in cancer patients.
2010-08
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
2010-08
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
2010-08
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
2010-07
Gateways to clinical trials.
2010-06
Drug and dietary interactions of the new and emerging oral anticoagulants.
2010-06
Old versus new anticoagulants: focus on pharmacology.
2010-06
Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis.
2010-06
[A new deal with new anticoagulants?].
2010-06
New anticoagulants for the prevention of venous thromboembolism.
2010-05-25
New options with dabigatran etexilate in anticoagulant therapy.
2010-05-25
Forecasting drug utilization and expenditure in a metropolitan health region.
2010-05-17
Emerging anticoagulants for venous thromboembolism prevention.
2010-05-15
Primary prevention of venous thromboembolism in medical and surgical oncology patients.
2010-04-13
Health trends.
2010-04
Potential of new anticoagulants in patients with cancer.
2010-04
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
2010-04
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
2010-04
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
2010-03-06
Apixaban to prevent venous thromboembolism after knee replacement.
2010-03-06
[Pulmonary circulation: contributions of the year 2009].
2010-03
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
2010-03
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
2010-03
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.
2010-03
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
2010-03
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
2010-03
Phenyltriazolinones as potent factor Xa inhibitors.
2010-02-15
New oral anticoagulants: a practical guide for clinicians.
2010-02
The new oral anticoagulants.
2010-01-07
Apixaban: an emerging oral factor Xa inhibitor.
2010-01
Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.
2010-01
Novel anticoagulant therapy: principle and practice.
2010
New oral anticoagulants in development: potential for improved safety profiles.
2010
Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
2009-12
Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.
2009-12
Apixaban or enoxaparin for thromboprophylaxis.
2009-11-19
Gateways to clinical trials.
2009-11
New antithrombotic drugs: potential for use in oncology.
2009-10-10
Gateways to clinical trials.
2009-10
[New developments in antithrombotic care].
2009-09
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
2009-08-06
New anticoagulants for atrial fibrillation.
2009-07
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.
2009
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.
2009
Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.
2008
Patents

Patents

06919451
1
07153960
1
JP2010539945A
2
JP2011502514A
9
JP2011502515A
9

Sample Use Guides

In Vivo Use Guide
The recommended dose is 5 mg orally twice daily. In patients with at least 2 of the following characteristics: age 80 years, body weight 60 kg, or serum creatinine 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:15:37 GMT 2025
Edited
by admin
on Mon Mar 31 18:15:37 GMT 2025
Record UNII
3Z9Y7UWC1J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
APIXABAN
DASH   EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ELIQUIS
Preferred Name English
APIXABAN [EMA EPAR]
Common Name English
APIXABAN [VANDF]
Common Name English
1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXOPIPERIDIN-1-YL)PHENYI)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO(3,4-C)PYRIDINE-3-CARBOXAMIDE
Common Name English
APIXABAN [JAN]
Common Name English
APIXABAN [MART.]
Common Name English
BMS-562247
Code English
APIXABAN [MI]
Common Name English
BMS-562247-01
Code English
Apixaban [WHO-DD]
Common Name English
APIXABAN [ORANGE BOOK]
Common Name English
1H-PYRAZOLO(3,4-C)PYRIDINE-3-CARBOXAMIDE, 4,5,6,7-TETRAHYDRO-1-( 4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-
Common Name English
apixaban [INN]
Common Name English
APIXABAN [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548281
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
WHO-ATC B01AF02
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
NCI_THESAURUS C263
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
EMA ASSESSMENT REPORTS ELIQUIS (AUTHORIZED: ARTHROPLASTY)
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
LOINC 74214-8
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
WHO-VATC QB01AF02
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
EMA ASSESSMENT REPORTS ELIQUIS (AUTHORIZED: VENOUS THROMBOEMBOLISM)
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
NDF-RT N0000175637
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
Code System Code Type Description
SMS_ID
100000091294
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
IUPHAR
6390
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
FDA UNII
3Z9Y7UWC1J
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
EVMPD
SUB25425
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
INN
8626
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
JAPANESE REVIEW
ELIQUIS
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY APPROVED DECEMBER 2012
MESH
C522181
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
ChEMBL
CHEMBL231779
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
MERCK INDEX
m1993
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY Merck Index
CAS
503612-47-3
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
DAILYMED
3Z9Y7UWC1J
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
LACTMED
Apixaban
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
CHEBI
72296
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
HSDB
8223
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
PUBCHEM
10182969
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
WIKIPEDIA
APIXABAN
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
RXCUI
1364430
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB06605
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
USAN
QQ-78
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
NCI_THESAURUS
C61308
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID80436500
Created by admin on Mon Mar 31 18:15:37 GMT 2025 , Edited by admin on Mon Mar 31 18:15:37 GMT 2025
PRIMARY
DRUG CENTRAL
4298
Created by admin on Mon Mar 31 18:15:38 GMT 2025 , Edited by admin on Mon Mar 31 18:15:38 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> NON-INDUCER
In human hepatocytes.
Structure of APIXABAN
EXCRETED UNCHANGED
URINE
CYTOCHROME P450 2B6
METABOLIC ENZYME -> NON-INDUCER
In human hepatocytes.
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C19
METABOLIC ENZYME -> NON-INHIBITOR
COAGULATION FACTOR X HUMAN
TARGET -> INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> NON-INHIBITOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> NON-INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
FACTOR XA
TARGET -> INHIBITOR
CYTOCHROME P450 2C9
METABOLIC ENZYME -> NON-INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> NON-INHIBITOR
Structure of APIXABAN
EXCRETED UNCHANGED
FECAL
CYTOCHROME P450 1A2
METABOLIC ENZYME -> NON-INDUCER
In human hepatocytes.
CYTOCHROME P450 1A2
METABOLIC ENZYME -> NON-INHIBITOR
Related Record Type Details
Structure of O-DEMETHYL APIXABAN
METABOLITE -> PARENT
MINOR
Structure of O-DEMETHYL APIXABAN SULFATE
METABOLITE -> PARENT
MAJOR
PLASMA
Related Record Type Details
Structure of Ethyl 1-(4-methoxyphenyl)-6-(4-nitrophenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
IMPURITY -> PARENT
Structure of 3,3-Dichloro-1-(4-nitrophenyl)piperidin-2-one
IMPURITY -> PARENT
Structure of Ethyl 6-[4-[(5-bromo-1-oxopentyl)amino]phenyl]-4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
IMPURITY -> PARENT
Structure of Apixaban acid
IMPURITY -> PARENT
Structure of Methyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
IMPURITY -> PARENT
Structure of 1-(4-Methoxyphenyl)-7a-morpholino-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-3a,4,5,6,7,7a-hexahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
IMPURITY -> PARENT
Structure of Chloroapixaban
IMPURITY -> PARENT
Structure of Apixaban open ring amide
IMPURITY -> PARENT
Structure of Apixaban open ring acid
IMPURITY -> PARENT
Structure of Apixaban ethyl ester
IMPURITY -> PARENT
Structure of N-Formyl-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
IMPURITY -> PARENT
Structure of Ethyl 6-[4-(5-chloropentanamido)phenyl]-1-(4-methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate
IMPURITY -> PARENT
Related Record Type Details
Structure of APIXABAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966